Please Wait.....
Report
Urinary Tract Infection Testing Market By Infection Type (Urethritis, Cystitis, Pyelonephritis), By Test Type (Urinalysis
Market Report I 2023-01-01 I 280 Pages I Allied Market Research
The global urinary tract infection testing market is anticipated to reach $1,027.4 million by 2031, increasing from$574 millionin 2021 at a CAGR of 6.2% from 2022 to 2031.
The rise in the prevalence of chronic diseases such as kidney disease and diabetes, an increase in the preference of clinicians for complete urine analysis, the surge in demand for early disease detection, a rise in cases of hospital-acquired urinary tract infection, and an increase in the use of urine analysis tests are the key factors driving the growth of the urinalysis test market. In addition, the rise in demand for minimally invasive urine diagnostic procedures, the increase in adoption of advanced urine analysis testing procedures, and the surge in R&D activities for the introduction of novel and accurate diagnostic tests are some factors that support the growth of the UTI testing market.
The global market for urinary tract infection testing is anticipated to experience development challenges due to side effects associated with the usage of UTI medications. Frequent errors in the diagnosis and management of urinary tract infection testing can impede market expansion during the forecast period. The lack of identifiable symptoms associated with UTI, the absence of standard diagnostic criteria, and the high contamination of samples are some of the key hurdles to market expansion.
Urinary tract infection (UTI) is a common occurrence in females, during pregnancy, and in peri- and postmenopausal women. UTIs are associated with severe morbidity and death, and they impact the quality of life of the affected people. Antibiotic therapy is a successful treatment that shortens the duration of symptoms. The development of resistance, the undesirable effects of antibiotics, and other linked issues lead to the establishment of a research framework to discover alternate means to managing UTIs.
Natural techniques are widely employed in the treatment of numerous ailments to alleviate symptoms and improve overall health.The use of medicinal herbs in the treatment and prevention of numerous diseases has expanded recently]. Complimentary therapy with medicinal herbs is a study topic that may merit special consideration. It has been demonstrated that herbal remedies can be useful in the management of a certain form of UTI.
Treatment with non-antibiotic drugs is a good strategy to lower the chance of developing UTI and to decrease its symptoms. Natural elements, minerals, and probiotics are among several agents that draw interest. Co-formulation of medications in a single dose form can create a natural formulation that is useful for both preventive and therapeutic methods in the management of UTI because each of these medications operates through a separate mechanism.
The COVID-19 pandemic brought several uncertainties, leading to severe economic losses as various businesses across the world were at a standstill. The arrival of the COVID-19 pandemic negatively impacted the manufacturing and supply chain & logistics industries, adversely affecting the healthcare business. Governments and healthcare providers are facing unheard-of issues owing to COVID-19, which has also had an impact on the regulatory environment and procedures. Patients with COVID-19 who were hospitalized were reportedly diagnosed with urinary tract infections. But multiple examinations have revealed that people with COVID-19 did not have severe urinary tract symptoms. Antibiotics are used extensively in COVID-19 patients due to high levels of blood inflammatory indicators of bacterial infection such as elevated C-reactive protein and procalcitonin. The majority of these individuals, however, had microbiologically verified bacterial co-infection symptoms.
The key players profiled in the report includeF. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the urinary tract infection testing market analysis from 2021 to 2031 to identify the prevailing urinary tract infection testing market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the urinary tract infection testing market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global urinary tract infection testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Test Kit
- Home Test Kits
- Laboratory Test Kits
By Infection Type
- Urethritis
- Cystitis
- Pyelonephritis
By Test Type
- Urinalysis
- Urine Cultures
- Susceptibility Testing
By End User
- Hospitals
- Diagnostic Laboratories
- Research Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA
- Key Market Players
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories
- Danaher Corporation
- ACON Laboratories Inc.
- Cardinal Health Inc.
- Stryker Corporation
- SYSMEX CORPORATION
- Abbott Laboratories
- Roche AG
- LabCorp(Laboratory Corporation of America Holdings).
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Key Regulation Analysis
3.7. Market Share Analysis
3.8. Patent Landscape
3.9. Regulatory Guidelines
3.10. Value Chain Analysis
CHAPTER 4: URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Urethritis
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Cystitis
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Pyelonephritis
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Urinalysis
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Urine Cultures
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Susceptibility Testing
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: URINARY TRACT INFECTION TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Research Institutes
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT
7.1. Overview
7.1.1. Market size and forecast
7.2. Home Test Kits
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Laboratory Test Kits
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: URINARY TRACT INFECTION TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Infection Type
8.2.3. Market size and forecast, by Test Type
8.2.4. Market size and forecast, by End User
8.2.5. Market size and forecast, by Test Kit
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Infection Type
8.2.6.1.3. Market size and forecast, by Test Type
8.2.6.1.4. Market size and forecast, by End User
8.2.6.1.5. Market size and forecast, by Test Kit
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Infection Type
8.2.6.2.3. Market size and forecast, by Test Type
8.2.6.2.4. Market size and forecast, by End User
8.2.6.2.5. Market size and forecast, by Test Kit
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Infection Type
8.2.6.3.3. Market size and forecast, by Test Type
8.2.6.3.4. Market size and forecast, by End User
8.2.6.3.5. Market size and forecast, by Test Kit
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Infection Type
8.3.3. Market size and forecast, by Test Type
8.3.4. Market size and forecast, by End User
8.3.5. Market size and forecast, by Test Kit
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Infection Type
8.3.6.1.3. Market size and forecast, by Test Type
8.3.6.1.4. Market size and forecast, by End User
8.3.6.1.5. Market size and forecast, by Test Kit
8.3.6.2. UK
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Infection Type
8.3.6.2.3. Market size and forecast, by Test Type
8.3.6.2.4. Market size and forecast, by End User
8.3.6.2.5. Market size and forecast, by Test Kit
8.3.6.3. France
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Infection Type
8.3.6.3.3. Market size and forecast, by Test Type
8.3.6.3.4. Market size and forecast, by End User
8.3.6.3.5. Market size and forecast, by Test Kit
8.3.6.4. Spain
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Infection Type
8.3.6.4.3. Market size and forecast, by Test Type
8.3.6.4.4. Market size and forecast, by End User
8.3.6.4.5. Market size and forecast, by Test Kit
8.3.6.5. Italy
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Infection Type
8.3.6.5.3. Market size and forecast, by Test Type
8.3.6.5.4. Market size and forecast, by End User
8.3.6.5.5. Market size and forecast, by Test Kit
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Infection Type
8.3.6.6.3. Market size and forecast, by Test Type
8.3.6.6.4. Market size and forecast, by End User
8.3.6.6.5. Market size and forecast, by Test Kit
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Infection Type
8.4.3. Market size and forecast, by Test Type
8.4.4. Market size and forecast, by End User
8.4.5. Market size and forecast, by Test Kit
8.4.6. Market size and forecast, by country
8.4.6.1. China
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Infection Type
8.4.6.1.3. Market size and forecast, by Test Type
8.4.6.1.4. Market size and forecast, by End User
8.4.6.1.5. Market size and forecast, by Test Kit
8.4.6.2. Japan
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Infection Type
8.4.6.2.3. Market size and forecast, by Test Type
8.4.6.2.4. Market size and forecast, by End User
8.4.6.2.5. Market size and forecast, by Test Kit
8.4.6.3. India
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Infection Type
8.4.6.3.3. Market size and forecast, by Test Type
8.4.6.3.4. Market size and forecast, by End User
8.4.6.3.5. Market size and forecast, by Test Kit
8.4.6.4. South Korea
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Infection Type
8.4.6.4.3. Market size and forecast, by Test Type
8.4.6.4.4. Market size and forecast, by End User
8.4.6.4.5. Market size and forecast, by Test Kit
8.4.6.5. Australia
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Infection Type
8.4.6.5.3. Market size and forecast, by Test Type
8.4.6.5.4. Market size and forecast, by End User
8.4.6.5.5. Market size and forecast, by Test Kit
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Infection Type
8.4.6.6.3. Market size and forecast, by Test Type
8.4.6.6.4. Market size and forecast, by End User
8.4.6.6.5. Market size and forecast, by Test Kit
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Infection Type
8.5.3. Market size and forecast, by Test Type
8.5.4. Market size and forecast, by End User
8.5.5. Market size and forecast, by Test Kit
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Infection Type
8.5.6.1.3. Market size and forecast, by Test Type
8.5.6.1.4. Market size and forecast, by End User
8.5.6.1.5. Market size and forecast, by Test Kit
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Infection Type
8.5.6.2.3. Market size and forecast, by Test Type
8.5.6.2.4. Market size and forecast, by End User
8.5.6.2.5. Market size and forecast, by Test Kit
8.5.6.3. United Arab Emirates
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Infection Type
8.5.6.3.3. Market size and forecast, by Test Type
8.5.6.3.4. Market size and forecast, by End User
8.5.6.3.5. Market size and forecast, by Test Kit
8.5.6.4. South Africa
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Infection Type
8.5.6.4.3. Market size and forecast, by Test Type
8.5.6.4.4. Market size and forecast, by End User
8.5.6.4.5. Market size and forecast, by Test Kit
8.5.6.5. Rest of LAMEA
8.5.6.5.1. Key market trends, growth factors and opportunities
8.5.6.5.2. Market size and forecast, by Infection Type
8.5.6.5.3. Market size and forecast, by Test Type
8.5.6.5.4. Market size and forecast, by End User
8.5.6.5.5. Market size and forecast, by Test Kit
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1. Abbott Laboratories
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.2. Roche AG
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.3. Thermo Fisher Scientific, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.4. Bio-Rad Laboratories
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.5. Danaher Corporation
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.6. ACON Laboratories Inc.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.7. Cardinal Health Inc.
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.8. Stryker Corporation
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.9. SYSMEX CORPORATION
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.10. LabCorp(Laboratory Corporation of America Holdings).
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
LIST OF TABLES
TABLE 01. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. URINARY TRACT INFECTION TESTING MARKET FOR URETHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. URINARY TRACT INFECTION TESTING MARKET FOR CYSTITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. URINARY TRACT INFECTION TESTING MARKET FOR PYELONEPHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 06. URINARY TRACT INFECTION TESTING MARKET FOR URINALYSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. URINARY TRACT INFECTION TESTING MARKET FOR URINE CULTURES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. URINARY TRACT INFECTION TESTING MARKET FOR SUSCEPTIBILITY TESTING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 10. URINARY TRACT INFECTION TESTING MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. URINARY TRACT INFECTION TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. URINARY TRACT INFECTION TESTING MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 14. URINARY TRACT INFECTION TESTING MARKET FOR HOME TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. URINARY TRACT INFECTION TESTING MARKET FOR LABORATORY TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. URINARY TRACT INFECTION TESTING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 20. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. U.S. URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 23. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. U.S. URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 26. CANADA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 29. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 30. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 34. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 39. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 40. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 43. UK URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. UK URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 46. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 50. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 51. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 55. ITALY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ITALY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 59. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 62. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 66. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 67. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 68. CHINA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. CHINA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 71. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 72. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 75. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 76. INDIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. INDIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 79. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 84. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 87. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 88. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 90. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 92. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 93. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 94. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 95. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 97. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 98. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 100. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 101. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 102. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 103. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 104. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 105. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 106. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 107. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 108. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 109. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 110. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 111. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 112. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 113. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 114. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 115. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 116. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
TABLE 117. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 118. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 119. ROCHE AG: KEY EXECUTIVES
TABLE 120. ROCHE AG: COMPANY SNAPSHOT
TABLE 121. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
TABLE 122. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 123. BIO-RAD LABORATORIES: KEY EXECUTIVES
TABLE 124. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
TABLE 125. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 126. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 127. ACON LABORATORIES INC.: KEY EXECUTIVES
TABLE 128. ACON LABORATORIES INC.: COMPANY SNAPSHOT
TABLE 129. CARDINAL HEALTH INC.: KEY EXECUTIVES
TABLE 130. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
TABLE 131. STRYKER CORPORATION: KEY EXECUTIVES
TABLE 132. STRYKER CORPORATION: COMPANY SNAPSHOT
TABLE 133. SYSMEX CORPORATION: KEY EXECUTIVES
TABLE 134. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 135. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: KEY EXECUTIVES
TABLE 136. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 01. URINARY TRACT INFECTION TESTING MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF URINARY TRACT INFECTION TESTING MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN URINARY TRACT INFECTION TESTING MARKET (2022-2031)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALURINARY TRACT INFECTION TESTING MARKET
FIGURE 10. IMPACT OF KEY REGULATION: URINARY TRACT INFECTION TESTING MARKET
FIGURE 11. MARKET SHARE ANALYSIS: URINARY TRACT INFECTION TESTING MARKET
FIGURE 12. PATENT ANALYSIS BY COMPANY
FIGURE 13. PATENT ANALYSIS BY COUNTRY
FIGURE 14. REGULATORY GUIDELINES: URINARY TRACT INFECTION TESTING MARKET
FIGURE 15. VALUE CHAIN ANALYSIS: URINARY TRACT INFECTION TESTING MARKET
FIGURE 16. URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URETHRITIS, BY COUNTRY 2021-2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR CYSTITIS, BY COUNTRY 2021-2031(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR PYELONEPHRITIS, BY COUNTRY 2021-2031(%)
FIGURE 20. URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URINALYSIS, BY COUNTRY 2021-2031(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URINE CULTURES, BY COUNTRY 2021-2031(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR SUSCEPTIBILITY TESTING, BY COUNTRY 2021-2031(%)
FIGURE 24. URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR HOSPITALS, BY COUNTRY 2021-2031(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2021-2031(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR RESEARCH INSTITUTES, BY COUNTRY 2021-2031(%)
FIGURE 28. URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021(%)
FIGURE 29. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR HOME TEST KITS, BY COUNTRY 2021-2031(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR LABORATORY TEST KITS, BY COUNTRY 2021-2031(%)
FIGURE 31. URINARY TRACT INFECTION TESTING MARKET BY REGION, 2021
FIGURE 32. U.S. URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 33. CANADA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 34. MEXICO URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 35. GERMANY URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 36. UK URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 37. FRANCE URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 38. SPAIN URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 39. ITALY URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 40. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 41. CHINA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 42. JAPAN URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 43. INDIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 44. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 45. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 46. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 47. BRAZIL URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 48. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 49. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 50. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 51. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 55. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 56. COMPETITIVE DASHBOARD
FIGURE 57. COMPETITIVE HEATMAP: URINARY TRACT INFECTION TESTING MARKET
FIGURE 58. TOP PLAYER POSITIONING, 2021
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security